- Home
- VLYPO vs CMMB Comparison
VLYPO vs CMMB Comparison
Compare VLYPO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLYPO
- CMMB
- Stock Information
- Founded
- VLYPO N/A
- CMMB 2004
- Country
- VLYPO United States
- CMMB Israel
- Employees
- VLYPO 3749
- CMMB N/A
- Industry
- VLYPO Major Banks
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- VLYPO Finance
- CMMB Health Care
- Exchange
- VLYPO Nasdaq
- CMMB Nasdaq
- Market Cap
- VLYPO N/A
- CMMB 37.3M
- IPO Year
- VLYPO N/A
- CMMB N/A
- Fundamental
- Price
- VLYPO $25.18
- CMMB $1.97
- Analyst Decision
- VLYPO
- CMMB Strong Buy
- Analyst Count
- VLYPO 0
- CMMB 2
- Target Price
- VLYPO N/A
- CMMB $7.50
- AVG Volume (30 Days)
- VLYPO N/A
- CMMB 82.4K
- Earning Date
- VLYPO N/A
- CMMB 03-06-2025
- Dividend Yield
- VLYPO N/A
- CMMB N/A
- EPS Growth
- VLYPO N/A
- CMMB N/A
- EPS
- VLYPO N/A
- CMMB N/A
- Revenue
- VLYPO N/A
- CMMB N/A
- Revenue This Year
- VLYPO N/A
- CMMB N/A
- Revenue Next Year
- VLYPO N/A
- CMMB N/A
- P/E Ratio
- VLYPO N/A
- CMMB N/A
- Revenue Growth
- VLYPO N/A
- CMMB N/A
- 52 Week Low
- VLYPO N/A
- CMMB $0.55
- 52 Week High
- VLYPO N/A
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- VLYPO 51.51
- CMMB 56.98
- Support Level
- VLYPO $25.00
- CMMB $2.02
- Resistance Level
- VLYPO $25.19
- CMMB $2.15
- Average True Range (ATR)
- VLYPO 0.10
- CMMB 0.12
- MACD
- VLYPO 0.00
- CMMB -0.01
- Stochastic Oscillator
- VLYPO 32.22
- CMMB 69.57
About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company whose principal wholly-owned subsidiary is Valley National Bank. It provides a full range of commercial, retail, and trust and investment services largely through its offices and ATM network throughout northern and central New Jersey, New York City Long Island, Florida, and Alabama. The segments of the group are commercial lending, consumer lending, investment management, and corporate and other adjustments, of which key interest income is derived from the commercial lending segment. In recent years, the company has focused on acquiring companies that operate outside of traditional banking and has emphasized wealth and capital management.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.